Skye Bioscience, Inc. (OTCQB: SKYE) CEO Punit Dhillon tells Proactive the San Diego, California-based biopharmaceutical company has changed its name from Emerald Bioscience, Inc. to Skye Bioscience, Inc. Dhillon says the name change reflects how 'the sky is limitless' for the group's robust pipeline on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need.
Skye Bioscience name change from Emerald Bioscience reflects 'limitless' strategy to treat glaucoma
